检索结果-南通市图书馆

Differential expression of the s100 gene family members in oral squamous cell carcinomas

中国口腔颌面外科杂志 2008年第B5期6卷 83-84页

作者： dipak sapkota Ove Bruland Endre N. Vasstrand salah O. Ibrahim Department of Biomedicine University of Bergen Bergen N5009 Norway Department of Periodontology University of Bergen Bergen N5009 Norway Centre for Medical Genetics and Molecular medicine Haukeland University Hospital University of Bergen Bergen N5021 Norway

Purpose: To examine the expression profile of 16 members of the s 100 gene family at the mRNA level by semiquantitative reverse transcription-polymerase chain reaction (sRT-PCR) in 27 cases of oral squamous cell carcinomas (OsCCs)/their pair-wised normal controls obtained from sudanese patients, and to confirm the sRT-PCR results by performing quantitative real time-polymerase chain reaction (qRT-PCR) for 6 of the 16 genes examined。Methods: Total RNA was extracted from all the OsCCs/normal controls, followed by cDNA synthesis and RT-PCR。For the sRT-PCR, gel electrophoretic images were captured and analyzed by Quantity one software。For the 6 genes examined by qRT-PCR, relative standard curve method was used to quantify the mRNA level。Wilcoxon matched-pair signed rank test was thereafter used for the statistical analysis。Results: With sRT-PCR, 4 (25%; s100A4, s100A6, s100A8, s100A14) out of the 16 s100 gene members examined were found to be significantly down regulated (Ps compared to the controls。None of the s 100 gene members examined were found to be significantly up regulated, qRT-PCR results confirmed the significant down regulation of the s 100A4, sI00A6 and sI00AI4 in the tumors examined。No significant association was found between the status of gene deregulation and patients' clinicopathological variables。Conclusions: s 100 gene family members might play an important role in the pathogenesis of the OsCCs examined。Findings of the present work warrant in-depth studies of the s 100 gene family members, in particular, the s100A4, s100A6, s100A8 and s100A14 to further understand their possible role(s) in OsCC tumorigenesis。

关键词：鳞状细胞癌口腔癌基因家族治疗方法

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pharmacokinetics/Pharmacodynamics study of Fixtral sB as compared to supra bioavailable itraconazole and conventional itraconazole

引用

World Journal of Pharmacology 2023年第1期12卷 1-11页

作者： syed Mujtaba Hussain Naqvi Monil Yogesh Neena Gala snehal Muchhala Anand Arumugam Dhananjay Panigrahi dipak Patil Rahul Rathod Amey Mane Medical Affairs Dr Reddy’s LaboratoriesHyderabad 500016India Global Clinical Management Dr Reddy’s LaboratoriesHyderabad 500016India Formulation Development Dr Reddy’s LaboratoriesHyderabad 500016India

BACkGROUND Itraconazole is a broad-spectrum triazole antifungal inhibiting fungal growth by inhibiting ergosterol synthesis and exhibits a nonlinear pharmacokinetic *** absorption pattern with wide fluctuations in blood levels causes inconsistent and unpredictable clinical behaviour of this drug despite its low minimum inhibitory concentration(MIC)as compared to other antifungal *** To compare the oral bioavailability and bioequivalence of Fixtral sB(supra bioavailable itraconazole)with reference product R2(supra bioavailable 2×50 mg itraconazole).METHODs The study population consisted of 54 healthy volunteers,aged between 18-45 years and randomized to receive a single oral dose of either test[T;Fixtral sB(supra bioavailable itraconazole)100 mg]or reference product(R1;sporanox 100 mg×2 capsules and R2;Lozanoc capsules 50 mg×2 capsules).Blood samples were taken pre-dose and post-dose up to 96 *** study evaluated bioequivalence by comparing the oral bioavailability of the test product with reference product *** pharmacodynamic characteristics of the drug were evaluated by comparing the test product with reference product ***(Pk)-PD comparative analysis[area under the concentration-time curve(AUC)/minimum inhibitory concentration(MIC)>25]was performed for conventional itraconazole 100 mg and supra bioavailable itraconazole 50 *** events(AEs)assessments were performed in each study period and post-study *** statistical analysis of primary Pk variables revealed bioequivalence,with confidence intervals being completely inside the acceptance criteria of 80%-125%.The peak concentration levels of itraconazole were achieved at 10 h(T)and 8.5 h(R2),*** parameter assessment showed that AUC/MIC for R1 are comparable to Fixtral sB 100mg for MIC levels up to 16mcg/mL(P>0.05 and observed P=0.3196).six AEs were observed that were mild to moderate in severity and *** severe AE was reported.

关键词： supra-Bioavailable itraconazole Conventional itraconazole Oral bioavailability Pharmacodynamics Efficacy Adverse events

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Interferon-γ: Promising therapeutic target in atherosclerosis

引用

World Journal of Experimental Medicine 2015年第3期5卷 154-159页

作者： Joe WE Moss dipak P Ramji Cardiff school of Biosciences Cardiff University

Atherosclerosis is a chronic inflammatory disorder of the vasculature and is the primary cause of cardiovascular disease(CVD). CVD is currently the world's leading cause of death and the numbers are predicted to rise further because of a global increase in risk factors such as diabetes and obesity. Current therapies such as statins have had a major impact in reducing mortality from CVD. However, there is a marked residual CVD risk in patients on statin therapy. It is therefore important to understand the molecular basis of this disease in detail and to develop alternative novel therapeutics. Interferon-γ(IFN-γ) is a pro-inflammatory cytokine that is often regarded as a master regulator of atherosclerosis development. IFN-γ is able to influence several key steps during atherosclerosis development, including pro-inflammatory gene expression, the recruitment of monocytes from the blood to the activated arterial endothelium and plaque stability. This central role of IFN-γ makes it a promising therapeutic target. The purpose of this editorial is to describe the key role IFN-γ plays during atherosclerosis development, as well as discuss potential strategies to target it therapeutically.

关键词： Atherosclerosis Interferon-γ Inflammation Neutralization MicroRNA

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CODE-EHR:临床研究中运用结构化电子医疗记录的最佳实践框架

引用

英国医学杂志中文版 2022年第12期25卷 721-729页

作者： dipak kotecha Folkert W Asselbergs stephan Achenbach stefan DAnker Dan Atars Colin Baigent Amitava Banerjee Birgit Beger Cunnar Brobert Barbara Casadei Cinzia Ceccarelli Martin R Cowie Filippo Crea Maureen Cronin spiros Denaxas Andrea Derix Donna Fitzsimons Martin Fredriksson Chris PGale Georgios V Ckoutos Wim Goettsch Harry Hemingway Martin Ingvaris Adrian Jonas's Robert kazmierski susanne Logstrup R Thomas Lumbers Thomas F Lischer Paul McGreavy leana L Pina Lothar Roesiga Carl steinbeisser Mats sundgren Benoit Tyl Chislaine van Thiel kees van Bochove Panos EVardas Tiago Villanueva Marilena Vrana Wim Weber Franz Weidinger stephan Windecker Angela Wood Diederick E Grobbee 创新药物计划BigData@Heart联盟欧洲心脏病协会 CODE-EHR国际共识小组宋奇繁(译) 汪奕名(译) 不详重庆医药高等专科学校

改善患者生存质量是全球临床医学的发展目标,大数据是实现其发展的关键所在。技术进步使结构化电子医疗记录得以常规化,也可能会改善缺失重要临床证据的问题。虽然大数据及其相关分析在新冠大流行期间发挥了重要作用,但也存在严重的缺... 详细信息

改善患者生存质量是全球临床医学的发展目标,大数据是实现其发展的关键所在。技术进步使结构化电子医疗记录得以常规化,也可能会改善缺失重要临床证据的问题。虽然大数据及其相关分析在新冠大流行期间发挥了重要作用,但也存在严重的缺陷。证实、核验、数据隐私以及对科学研究社会责任的践行是一项重要挑战。欧洲心脏病协会和BigData@Heart联盟已经收集了包括患者代表、临床医生、科研人员、监管机构、期刊编辑和企业代表在内的多元化国际参与者,提出了CODE-EHR的最低标准框架。为改进研究设计、提高信息透明度提供方法手段,同时为实现医疗保健数据的稳健并能够有效运用制定了技术路线图。

关键词：大数据数据隐私 CODE 技术路线图科研人员信息透明度医疗保健最低标准

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：